IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE

In re:	)	Chapter 11
SANGAMO THERAPEUTICS, INC.	)	Case No. 26-10989 (CTG)
Debtor.[1]	)	**Re: Docket Nos. 122, 139, 165, 209, 362, & 364**

NOTICE OF (I) CLOSING OF MEROPE SALE TRANSACTION, (II) ASSUMPTION AND ASSIGNMENT OF THE ACQUIRED CONTRACTS, AND (III) REJECTION OF THE REJECTED OUTBOUND LICENSE AGREEMENTS

PLEASE TAKE NOTICE that, on August 20, 2026, the United States Bankruptcy Court for the District of Delaware (the "**Court**") entered the *Order (A) Authorizing and Approving the Debtor's Entry into an Asset Purchase Agreement with Merope Acquisition Sub, LLC, (B) Authorizing the Sale of the Acquired Assets Free and Clear of all Claims and Interests, (C) Approving the Assumption and Assignment of the Acquired Contracts, (D) Authorizing the Rejection of Certain Executory Contracts, and (E) Granting Related Relief* [Docket No. 362] (the "**Merope Sale Order**").[2] The Merope Sale Order, among other things: (i) authorized the above-captioned debtor and debtor-in-possession (the "**Debtor**") to enter into that certain *Asset Purchase Agreement* (the "**Merope Purchase Agreement**") pursuant to which the Debtor agreed to sell (the "**Merope Sale Transaction**") the assets described in the Merope Purchase Agreement to Merope Acquisition Sub, LLC ("**Merope**"), (ii) authorized and approved the assumption and assignment of certain executory contracts and unexpired leases in connection with the Merope Sale Transaction, and (iii) authorized and approved the Debtor's rejection of certain executory contracts.

PLEASE TAKE FURTHER NOTICE that, on September 4, 2026 (the "**Closing Date**"), the Merope Sale Transaction closed.

PLEASE TAKE FURTHER NOTICE that, pursuant to the Merope Sale Order, effective as of the Closing Date: (i) the Acquired Contracts identified on **Exhibit 1a** hereto (the "**Acquired Contracts Exhibit**") were assumed by the Debtor and assigned to Merope, and (ii) the Rejected Outbound License Agreements identified on **Exhibit 2a** hereto (the "**Rejected Outbound License Agreements Exhibit**") were rejected by the Debtor.

PLEASE TAKE FURTHER NOTICE that, any claims arising out of the rejection of the Rejected Outbound License Agreements shall be filed in accordance with the *Order (I) Establishing Bar Dates and Related Procedures for Filing Proofs of Claim (Including for*

[1] The Debtor and the last four digits of its taxpayer identification number are: Sangamo Therapeutics, Inc. (9556). The Debtor's mailing address is 501 Canal Blvd., Ste A100, Richmond, CA 94804.

[2] Capitalized terms used but not defined herein have the meanings given to them in the Merope Sale Order.

2610989260904000000000004

Administrative Expense Claims Arising Under Section 503(b)(9) of the Bankruptcy Code), (II) Approving the Form and Manner of Notice Thereof, and (III) Granting Related Relief [Docket No. 209] by no later than **October 5, 2026 at 5:00 p.m. (Eastern Time)**.

PLEASE TAKE FURTHER NOTICE that: (i) a changed pages only blackline comparison of the Acquired Contracts Exhibit marked against the version of the Acquired Contracts Exhibit attached as Exhibit 2 to the Merope Sale Order is attached hereto as **Exhibit 1b**, and (ii) a blackline comparison of the Rejected Contract Exhibit marked against the list of contracts designated for rejection attached as Schedule 2 to the *Notice of Cure Amounts and Potential Assumption and Assignment and/or Rejection of Executory Contracts and Unexpired Leases in Connection with Sale of Substantially All Assets* [Docket No. 139] is attached hereto as **Exhibit 2b**.

[*Remainder of page intentionally left blank*]

Dated: September 4, 2026
Wilmington, Delaware

/s/ James F. McCauley

Daniel J. DeFranceschi (No. 2732)
Amanda R. Steele (No. 5530)
Brendan J. Schlauch (No. 6115)
James F. McCauley (No. 6991)
RICHARDS, LAYTON & FINGER, P.A.
One Rodney Square
920 N. King Street
Wilmington, Delaware 19801
Telephone: (302) 651-7700
Emails: defranceschi@rlf.com
steele@rlf.com
schlauch@rlf.com
mccauley@rlf.com
and

Cullen D. Speckhart
Lauren A. Reichardt
Miriam Peguero Medrano
COOLEY LLP
55 Hudson Yards
New York, NY 10001-2157
Telephone: (212) 479-6000
Emails: cspeckhart@cooley.com
lreichardt@cooley.com
mpegueromedrano@cooley.com
and

Robert L. Eisenbach III
COOLEY LLP
3 Embarcadero Center, 20th Floor
San Francisco, CA 94111-4004
Telephone: (415) 693-2000
Email: reisenbach@cooley.com

Counsel for the Debtor and Debtor in Possession

Exhibit 1a

Acquired Contracts Exhibit

Exhibit 1a

Acquired Contracts Exhibit

#	Contract Counterparty	Contract Description	Cure Amount
26[1]	Advanced Cell Diagnostics, Inc.	Amendment dated July 22, 2024	$0.00
29	Advanced Cell Diagnostics, Inc.	Amendment to Statement of Work, dated April 10, 2019	$0.00
30	Advanced Cell Diagnostics, Inc.	Amendment dated August 1, 2019	$0.00
31	Advanced Cell Diagnostics, Inc.	Change Order to Statement of Work dated February 28, 2022	$0.00
32	Advanced Cell Diagnostics, Inc.	Amendment to Statement of Work dated January 29, 2019	$0.00
33	Advanced Cell Diagnostics, Inc.	Change Orders #1-3 to Statement of Work dated July 24, 2024	$0.00
34	Advanced Cell Diagnostics, Inc.	Change Order to Work Order dated June 16, 2023	$0.00
35	Advanced Cell Diagnostics, Inc.	Statement of Work dated June 28, 2017	$0.00
36	Advanced Cell Diagnostics, Inc.	Amendment to Statement of Work dated June 8, 2017	$0.00
37	Advanced Cell Diagnostics, Inc.	Amendment dated March 23, 2024	$0.00
38	Advanced Cell Diagnostics, Inc.	Change Order to Statement of Work dated November 4, 2022	$0.00
39	Advanced Cell Diagnostics, Inc.	Change Orders #1-5 to Statement of Work dated October 21, 2019	$0.00
40	Advanced Cell Diagnostics, Inc.	Exclusive Probe Request Form dated October 26, 2018	$0.00
41	Advanced Cell Diagnostics, Inc.	Amendment to Statement of Work dated October 3, 2017	$0.00
43	Advanced Cell Diagnostics, Inc.	Change orders 1-4 to SOW #15 dated July 10, 2019	$0.00

[1] Contract numbers correspond to the numbers used on Schedule 1 to the *Notice of Cure Amounts and Potential Assumption and Assignment and/or Rejection of Executory Contracts and Unexpired Leases in Connection with Sale of Substantially All Assets* [Docket No. 139], if applicable.

#	Contract Counterparty	Contract Description	Cure Amount
45	Advanced Cell Diagnostics, Inc.	Master Service Agreement, dated June 25, 2015, as amended and restated on March 24, 2017	$0.00
46	Advanced Cell Diagnostics, Inc.	Product Quote No. Q-635344, dated September 17, 2025	$0.00
49	Advanced Cell Diagnostics, Inc.	Statement of Work dated April 25, 2018	$0.00
50	Advanced Cell Diagnostics, Inc.	Statement of Work dated August 18, 2017	$0.00
52	Advanced Cell Diagnostics, Inc.	Statement of Work dated February 25, 2020	$0.00
53	Advanced Cell Diagnostics, Inc.	Statement of Work dated January 10, 2018	$0.00
54	Advanced Cell Diagnostics, Inc.	Statement of Work dated January 20, 2022	$0.00
55	Advanced Cell Diagnostics, Inc.	Statement of Work dated July 12, 2017	$0.00
56	Advanced Cell Diagnostics, Inc.	Statement of Work dated June 22, 2021	$0.00
57	Advanced Cell Diagnostics, Inc.	Statement of Work dated June 5, 2018	$0.00
58	Advanced Cell Diagnostics, Inc.	Statement of Work dated March 1, 2018	$0.00
60	Advanced Cell Diagnostics, Inc.	Statement of Work dated March 24, 2017	$0.00
61	Advanced Cell Diagnostics, Inc.	Statement of Work dated November 26, 2018	$0.00
62	Advanced Cell Diagnostics, Inc.	Statement of Work dated November 7, 2018	$0.00
63	Advanced Cell Diagnostics, Inc.	Statement of Work dated October 2, 2018	$0.00

#	Contract Counterparty	Contract Description	Cure Amount
64	Advanced Cell Diagnostics, Inc.	Statement of Work dated September 27, 2017	$0.00
65	Advanced Cell Diagnostics, Inc.	Work Order #14 (SP-002085), dated August 3, 2018	$0.00
66	Advanced Cell Diagnostics, Inc.	Work Order #5 with HALO Addendum (SP-001483/SP-001614), dated September 27, 2017	$0.00
98	ARC Regulatory Limited	Master Agreement dated September 20, 2025	$0.00
99	ARC Regulatory Limited	Statement of Work dated September 20, 2025	$0.00
444	California Institute of Technology	Agreement dated May 30, 2023	$20,000.00
459	Catalent Maryland, Inc.	Contract Change Order dated January 23, 2026	$0.00
461	Catalent Maryland, Inc.	Cell Bank Generation and Characterization for ST-504 (rAAV9)	$0.00
462	Catalent Maryland, Inc.	Master Agreement dated September 10, 2024	$742,500.17
463	Catalent Maryland, Inc.	Technology Transfer dated July 14, 2025	$0.00
480	Charles River Laboratories	Amended Statement of Work No.1, dated April 12, 2021	$0.00
482	Charles River Laboratories Montreal ULC	Amended Statement of Work No.1, dated July 15, 2022	$0.00
483	Charles River Laboratories Montreal ULC	Amended Statement of Work dated April 16, 2021	$0.00
490	Charles River Laboratories Montreal ULC	Statement of Work - A 15-day Biodistribution Study of Three Novel Brain Penetrant AAV Capsid Libraries after Intravenous Administration in	$0.00

#	Contract Counterparty	Contract Description	Cure Amount
		Cynomolgus Monkeys, dated May 3, 2021	
486	Charles River Laboratories Montreal ULC	Amended Statement of Work dated December 6, 2021	$0.00
487	Charles River Laboratories Montreal ULC	Amended Statement of Work No.4 dated July 15, 2022	$0.00
488	Charles River Laboratories Montreal ULC	Amended Statement of Work dated June 24, 2022	$0.00
489	Charles River Laboratories Montreal ULC	Amended Statement of Work dated November 14, 2022	$0.00
493	Charles River Laboratories Montreal ULC	Statement of Work dated December 6, 2021	$0.00
494	Charles River Laboratories Montreal ULC	Amended Statement of Work dated March 6, 2022	$0.00
495	Charles River Laboratories Montreal ULC	Statement of Work dated November 19, 2020	$0.00
497	Charles River Laboratories Montreal ULC	Statement of Work, dated April 17, 2021	$0.00
498	Charles River Laboratories Montréal ULC	Statement of Work dated July 16, 2025	$0.00
499	Charles River Laboratories Montréal ULC	Amended Statement of Work dated March 26, 2026	$0.00
500	Charles River Laboratories Montréal ULC	Statement of Work dated September 25, 2025	$0.00
505	Charles River Laboratories, Inc.	Amendment dated April 1, 2022	$0.00
525	Charles River Laboratories, Inc.	Amendment dated March 17, 2021	$0.00
529	Charles River Laboratories, Inc.	Amendment dated May 23, 2012	$0.00
531	Charles River Laboratories, Inc.	Amendment dated October 27, 2017	$0.00
538	Charles River Laboratories, Inc.	Master Agreement dated August 17, 2005	$467,997.00
712	Eli Lilly and Company	Research Agreement dated January 20, 2026	$0.00

#	Contract Counterparty	Contract Description	Cure Amount
713	Elim Biopharmaceuticals, Inc.	Master Services Agreement, dated December 3, 2025	$1,749.03
802	GemPharmatech Corporation	Master Agreement dated October 21, 2025	$0.00
803	GemPharmatech LLC	Statement of Work SNG-003, dated October 16, 2025	$0.00
807	GemPharmatech, LLC	Statement of Work Amendment 1, dated January 29, 2026	$0.00
810	GemPharmatech Corporation	Statement of Work SNG-004, dated January 27, 2026	$2,609.00
811	GemPharmatech, LLC	Statement of Work SNG-006, dated December 19, 2025	$22,075.50
812	GemPharmatech, LLC	Statement of Work SNG-007, dated January 12, 2026	$6,190.50
813	GemPharmatech, LLC	Statement of Work SNG-008, dated May 26, 2026	$0.00
1098	Memorial Sloan-Kettering Cancer Center; Sloan Kettering Institute for Cancer Research; Memorial Hospital for Cancer and Allied Diseases	Non-Exclusive License Agreement, dated December 21, 2022	$0.00
1120	MP Biomedicals, LLC	Quotation dated April 24, 2026	$0.00
1121	MP Biomedicals, LLC	FastPrep-96™ Pro Instrument Demo Agreement	$2,908.74
1350	Prevail Therapeutics, Inc.	Agreement dated April 2, 2025	$0.00
1351	Eli Lilly and Company	Side Letter, dated September 23, 2025, by and between Seller and Eli Lilly and Company (the "Lilly Side Letter").	$0.00
1524	Life Technologies Corporation	Agreement dated October 2, 2024	$76,659.66

#	Contract Counterparty	Contract Description	Cure Amount
N/A[2]	Alexion Pharmaceuticals, Inc.	Research Collaboration and License Agreement, dated December 28, 2017, as amended and restated by the Debtor, the Buyer, and Alexion Pharmaceuticals, Inc., on August 17, 2026	$0.00
N/A	Open Monoclonal Technology, Inc.	License Agreement, dated April 2, 2008, as amended and restated by the Debtor, the Buyer, and Open Monoclonal Technology, Inc., on August 17, 2026	$0.00
N/A	Astellas Gene Therapies, Inc.	License Agreement, dated December 18, 2024, as amended and restated by the Debtor, the Buyer, and Astellas Gene Therapies, Inc., on August 20, 2026	$0.00
N/A	Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.	Research and License Agreement, dated July 2, 2008, as amended and restated by the Debtor, the Buyer, and Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., on August 20, 2026	$0.00
N/A[3]	The General Hospital Corp. (d/b/a Massachusetts General Hospital) 55 Fruit Street Boston, Massachusetts 02144	That certain *Research Agreement*, dated June 1, 2015, as amended	$0.00

[2] The counterparties to the Alexion Agreement, OMT Agreement, Astellas Agreement, and Roche Agreement (each as defined in the Merope Sale Order) consented to the assumption and assignment of their respective agreements to Merope.

[3] That certain Research Agreement dated June 1, 2015, by and between Sangamo Therapeutics Inc. and The General Hospital Corp. (d/b/a Massachusetts General Hospital), as amended, was noticed for assumption and assignment in the *Notice of Addition to Acquired Contracts Exhibit to Merope Sale Order* [Dckt. No. 364].

Exhibit 1b

Acquired Cotracts Exhibit Redline

Acquired Contracts Exhibit

#	Contract Counterparty	Contract Description	Cure Amount
26[1]	Advanced Cell Diagnostics, Inc.	Amendment dated July 22, 2024	$0.00
29	Advanced Cell Diagnostics, Inc.	Amendment to Statement of Work, dated April 10, 2019	$0.00
30	Advanced Cell Diagnostics, Inc.	Amendment dated August 1, 2019	$0.00
31	Advanced Cell Diagnostics, Inc.	Change Order to Statement of Work dated February 28, 2022	$0.00
32	Advanced Cell Diagnostics, Inc.	Amendment to Statement of Work dated January 29, 2019	$0.00
33	Advanced Cell Diagnostics, Inc.	Change Orders #1-3 to Statement of Work dated July 24, 2024	$0.00
34	Advanced Cell Diagnostics, Inc.	Change Order to Work Order dated June 16, 2023	$0.00
35	Advanced Cell Diagnostics, Inc.	Statement of Work dated June 28, 2017	$0.00
36	Advanced Cell Diagnostics, Inc.	Amendment to Statement of Work dated June 8, 2017	$0.00
37	Advanced Cell Diagnostics, Inc.	Amendment dated March 23, 2024	$0.00
38	Advanced Cell Diagnostics, Inc.	Change Order to Statement of Work dated November 4, 2022	$0.00
39	Advanced Cell Diagnostics, Inc.	Change Orders #1-5 to Statement of Work dated October 21, 2019	$0.00
40	Advanced Cell Diagnostics, Inc.	Exclusive Probe Request Form dated October 26, 2018	$0.00
41	Advanced Cell Diagnostics, Inc.	Amendment to Statement of Work dated October 3, 2017	$0.00
43	Advanced Cell Diagnostics, Inc.	Change orders 1-4 to SOW #15 dated July 10, 2019	$0.00

[1] Contract numbers correspond to the numbers used on Schedule 1 to the *Notice of Cure Amounts and Potential Assumption and Assignment and/or Rejection of Executory Contracts and Unexpired Leases in Connection with Sale of Substantially All Assets* [Docket No. 139], if applicable.

#	Contract Counterparty	Contract Description	Cure Amount
713	Elim Biopharmaceuticals, Inc.	Master Services Agreement, dated December 3, 2025	$1,749.03
802	GemPharmatech Corporation	Master Agreement dated October 21, 2025	$0.00
803	GemPharmatech LLC	Statement of Work SNG-003, dated October 16, 2025	$0.00
807	GemPharmatech, LLC	Statement of Work Amendment 1, dated January 29, 2026	$0.00
810	GemPharmatech Corporation	Statement of Work SNG-004, dated January 27, 2026	$2,609.00
811	GemPharmatech, LLC	Statement of Work SNG-006, dated December 19, 2025	$22,075.50
812	GemPharmatech, LLC	Statement of Work SNG-007, dated January 12, 2026	$6,190.50
813	GemPharmatech, LLC	Statement of Work SNG-008, dated May 26, 2026	$0.00
1098	Memorial Sloan-Kettering Cancer Center; Sloan Kettering Institute for Cancer Research; Memorial Hospital for Cancer and Allied Diseases	Non-Exclusive License Agreement, dated December 21, 2022	$0.00
1120	MP Biomedicals, LLC	Quotation dated April 24, 2026	$0.00
1121	MP Biomedicals, LLC	FastPrep-96™ Pro Instrument Demo Agreement	$2,908.74
1350	Prevail Therapeutics, Inc.	Agreement dated April 2, 2025	$0.00
1351	Eli Lilly and Company	Side Letter, dated September 23, 2025, by and between Seller and Eli Lilly and Company (the "Lilly Side Letter").	$0.00
1524	Life Technologies Corporation	Agreement dated October 2, 2024	$76,659.66

#	Contract Counterparty	Contract Description	Cure Amount
N/A[2]	Alexion Pharmaceuticals, Inc.	Research Collaboration and License Agreement, dated December 28, 2017, as amended and restated by the Debtor, the Buyer, and Alexion Pharmaceuticals, Inc., on August 17, 2026	$~~0~~0.00
N/A	Open Monoclonal Technology, Inc.	License Agreement, dated April 2, 2008, as amended and restated by the Debtor, the Buyer, and Open Monoclonal Technology, Inc., on August 17, 2026	$~~0~~0.00
N/A	Astellas Gene Therapies, Inc.	License Agreement, dated December 18, 2024, as amended and restated by the Debtor, the Buyer, and Astellas Gene Therapies, Inc., on August ~~19~~20, 2026	$~~0~~0.00
N/A	Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.	Research and License Agreement, dated July 2, 2008, as amended and restated by the Debtor, the Buyer, and Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., on August 20, 2026	$~~0~~0.00
N/A[3]	The General Hospital Corp. (d/b/a Massachusetts General Hospital) 55 Fruit Street Boston, Massachusetts 02144	That certain *Research Agreement*, dated June 1, 2015, as amended	$0.00

[2] The counterparties to the Alexion Agreement, OMT Agreement, Astellas Agreement, and Roche Agreement (each as defined in the Merope Sale Order) consented to the assumption and assignment of their respective agreements to Merope.

[3] That certain Research Agreement dated June 1, 2015, by and between Sangamo Therapeutics Inc. and The General Hospital Corp. (d/b/a Massachusetts General Hospital), as amended, was noticed for assumption and assignment in the *Notice of Addition to Acquired Contracts Exhibit to Merope Sale Order* [Dckt. No. 364].

Exhibit 2a

Rejected Outbound License Agreements Exhibit

Exhibit 2a

Rejected Contracts Exhibit

No.[1]	Counterparty	Counterparty Address(es)	Agreement
1	Agriculture Victoria Services PTY LTD	5 Ring Road Bundoora, VIC 3083 Austria	Research License Agreement, dated October 1, 2013, as amended
N/A[2]	Agriculture Victoria Services PTY LTD	475 Mickleham Road, Attwood, VIC, Australia 3049	Commercial License Agreement dated June 1, 2016, as amended
2	Agrisoma Biosciences, Inc.	89 des Montagnais Street Gatineau, QC J9J 2M9 Canada	Research and Commercial License Agreement, dated February 1, 2014, as amended
5	Corteva Agriscience LLC (f/k/a Dow AgroSciences LLC)	9330 Zionsville Road Indianapolis, IN 46268	Research and Commercial License Option Agreement, dated October 1, 2005, as amended
7	Genentech, Inc.	1 DNA Way South San Francisco, CA 94080	License Agreement, dated August 2, 2024
8	Miltenyi Biotec B.V. & Co. KG	Friedrich-Ebert-Straße 68 Bergisch Gladbach 51429 Germany	License Agreement, dated November 12, 2025
10	Pfizer Inc.	66 Hudson Boulevard East New York, NY 10001-2192	License Agreement, dated December 19, 2008, as amended
11	Saatzucht Josef Breun GmbH & Co. KG	Amselweg 1 Herzogenaurach 91074 Germany	Research and Commercial License Agreement, dated November 9, 2012, as amended
12	Shire International GmbH	Thurgauerstrasse 130 Glattpark (Opfikon) ZH 8152 Switzerland	Amended and Restated Collaboration Agreement, dated September 1, 2015, as amended
13	Sigma-Aldrich Co.	3050 Spruce Street St. Louis, MO 63103	License Agreement, dated July 10, 2007, as amended
14	UBS Securities LLC	1285 Avenue of the Americas New York, NY 10019	Copyright Licensing Agreement, dated February 11, 2021

[1] Contract numbers correspond to the numbers used on Schedule 2 to the *Notice of Cure Amounts and Potential Assumption and Assignment and/or Rejection of Executory Contracts and Unexpired Leases in Connection with Sale of Substantially All Assets* [Docket No. 139], if applicable.

[2] That certain Commercial License Agreement dated June 1, 2016, by and between Sangamo Therapeutics Inc. and Agriculture Victoria Services PTY LTD, as amended, was noticed for rejection in the *First Supplemental Notice of Rejection of Executory Contracts and Unexpired Leases in Connection With Sale of Substantially All Assets* [Dckt. No. 165].

Exhibit 2b

Rejected Outbound License Agreements Exhibit Redline

No.[1]	Counterparty	Counterparty Address(es)	Agreement
~~1~~ 1	Agriculture Victoria Services PTY LTD	5 Ring Road Bundoora, VIC 3083 Austria	Research License Agreement, dated October 1, 2013, as amended
N/A[2]	Agriculture Victoria Services PTY LTD	475 Mickleham Road, Attwood, VIC, Australia 3049	Commercial License Agreement dated June 1, 2016, as amended
~~2~~ 2	Agrisoma Biosciences, Inc.	89 des Montagnais Street Gatineau, QC J9J 2M9 Canada	Research and Commercial License Agreement, dated February 1, 2014, as amended
~~3~~	~~Alexion Pharmaceuticals, Inc.~~	~~121 Seaport Boulevard Boston, MA 02210~~	~~Research Collaboration and License Agreement, dated December 28, 2017, as amended~~
~~4~~	~~Astellas Gene Therapies, Inc.~~	~~480 Forbes Boulevard South San Francisco, CA 94080~~	~~License Agreement, dated December 18, 2024~~
~~5~~ 5	Corteva Agriscience LLC (f/k/a Dow AgroSciences LLC)	9330 Zionsville Road Indianapolis, IN 46268	Research and Commercial License Option Agreement, dated October 1, 2005, as amended
~~6~~	~~F. Hoffmann-La Roche Ltd & Hoffmann-La Roche Inc.~~	~~150 Clove Road Suite 8 Little Falls, NJ 07424~~	~~Research and License Agreement, dated July 2, 2008~~
~~7~~ 7	Genentech, Inc.	1 DNA Way South San Francisco, CA 94080	License Agreement, dated August 2, 2024
~~8~~ 8	Miltenyi Biotec B.V. & Co. KG	Friedrich-Ebert-Straße 68 Bergisch Gladbach 51429 Germany	License Agreement, dated November 12, 2025
~~9~~	~~Open Monoclonal Technology, Inc.~~	~~5980 Horton Street Suite 600 Emeryville, CA 94608~~	~~License Agreement, dated April 2, 2008, as amended~~
~~10~~ 10	Pfizer Inc.	66 Hudson Boulevard East New York, NY 10001-2192	License Agreement, dated December 19, 2008, as amended

[1] Contract numbers correspond to the numbers used on Schedule 2 to the *Notice of Cure Amounts and Potential Assumption and Assignment and/or Rejection of Executory Contracts and Unexpired Leases in Connection with Sale of Substantially All Assets* [Docket No. 139], if applicable.

[2] That certain Commercial License Agreement dated June 1, 2016, by and between Sangamo Therapeutics Inc. and Agriculture Victoria Services PTY LTD, as amended, was noticed for rejection in the *First Supplemental Notice of Rejection of Executory Contracts and Unexpired Leases in Connection With Sale of Substantially All Assets* [Dckt. No. 165].

No.[1]	Counterparty	Counterparty Address(es)	Agreement
~~11~~ 11	Saatzucht Josef Breun GmbH & Co. KG	Amselweg 1 Herzogenaurach 91074 Germany	Research and Commercial License Agreement, dated November 9, 2012, as amended
~~12~~ 12	Shire International GmbH	Thurgauerstrasse 130 Glattpark (Opfikon) ZH 8152 Switzerland	Amended and Restated Collaboration Agreement, dated September 1, 2015, as amended
~~13~~ 13	Sigma-Aldrich Co.	3050 Spruce Street St. Louis, MO 63103	License Agreement, dated July 10, 2007, as amended
~~14~~ 14	UBS Securities LLC	1285 Avenue of the Americas New York, NY 10019	Copyright Licensing Agreement, dated February 11, 2021